SCHEMBL29904247

SCHEMBL29904247

CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2ccc(C#N)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 18/20 0.62
CYP3A4 P08684 1/20 0.49
PDK1 Q15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734763 0.90 GRM2 (0.65) GRM2CYP3A4
SCHEMBL6738838 0.88 GRM2 (0.62) GRM2
SCHEMBL6732204 0.88 GRM2 (0.78) GRM2CYP3A4
SCHEMBL6733186 0.88 GRM2 (0.78) GRM2
SCHEMBL6727500 0.83 GRM2 (0.69) GRM2CYP3A4
SCHEMBL6733481 0.82 GRM2 (0.65) GRM2CYP3A4
SCHEMBL6735945 0.81 GRM2 (0.78) GRM2
SCHEMBL6733070 0.81 GRM2 (0.60) GRM2CYP3A4
SCHEMBL6733084 0.81 GRM2 (0.80) GRM2
SCHEMBL6738584 0.80 GRM2 (0.47) GRM2CYP3A4PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098030-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 UNIV VANDERBILT (US) 2026-04-09 US disclosed
EP-4673136-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 Vanderbilt University (US) 2026-01-07 EP disclosed
EP-4568944-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 Vanderbilt University (US) 2025-06-18 EP disclosed
WO-2024182692-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2024-09-06 WO disclosed
US-20240208983-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY 2024-06-27 US disclosed
US-20240199641-A1 QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 UNIV VANDERBILT (US) 2024-06-20 US disclosed
US-20240199640-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY 2024-06-20 US disclosed
US-20230126310-A1 COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION FRAUNHOFER GES FORSCHUNG (DE) 2023-04-27 US disclosed
US-11472806-B2 Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors DOMAIN THERAPEUTICS (FR) 2022-10-18 US disclosed
WO-2022212815-A1 QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2022-10-06 WO disclosed
WO-2022212818-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2022-10-06 WO disclosed
WO-2022198003-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199640-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRIN2A, GRIN2C GRM2 1/4885CYP3A4 4028/4885PDK1 1934/4885
US-20240199641-A1 QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRIN2A, GRIN2C GRM2 1/4885CYP3A4 2764/4885PDK1 1828/4885
US-20260098030-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRM1, GRIN2C GRM2 1/4885CYP3A4 2043/4885PDK1 2488/4885
US-20240208983-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRM1, GRM3 GRM2 1/4885CYP3A4 2530/4885PDK1 1174/4885
US-11472806-B2 Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors GRM3, GRM1, GRM2 GRM2 3/4885CYP3A4 2911/4885PDK1 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.